Analyst Ratings For Pacira Pharmaceuticals (NASDAQ:PCRX)
Today, Royal Bank of Canada lowered its price target on Pacira Pharmaceuticals (NASDAQ:PCRX) to per share.
Some recent analyst ratings include
- 3/1/2018-Oppenheimer Reiterated Rating of Hold.
- 2/16/2018-Needham & Company LLC was Downgraded by analysts at Needham & Company LLC from a “Buy ” rating to a ” Hold” rating. They now have a $55.00 price target on the stock.
- 2/16/2018-Barclays Reiterated Rating of Buy.
- 2/16/2018-Canaccord Genuity Reiterated Rating of Hold.
- On 1/10/2018 David M. Stack, CEO, sold 28,885 with an average share price of $40.19 per share and the total transaction amounting to $1,160,888.15.
- On 12/15/2017 Lauren Bullaro Riker, VP, sold 340 with an average share price of $43.70 per share and the total transaction amounting to $14,858.00.
- On 11/20/2017 James B. Jones, SVP, sold 850 with an average share price of $41.11 per share and the total transaction amounting to $34,943.50.
- On 11/17/2017 Kristen Marie Williams, CAO, sold 10,000 with an average share price of $40.00 per share and the total transaction amounting to $400,000.00.
- On 11/15/2017 David M Stack, CEO, sold 58,885 with an average share price of $38.34 per share and the total transaction amounting to $2,257,650.90.
- On 11/10/2017 Mark A Kronenfeld, Director, bought 1,000 with an average share price of $41.60 per share and the total transaction amounting to $41,600.00.
- On 8/22/2017 Paul J Hastings, Director, sold 1,044 with an average share price of $36.15 per share and the total transaction amounting to $37,740.60.
Recent Trading Activity for Pacira Pharmaceuticals (NASDAQ:PCRX)
Shares of Pacira Pharmaceuticals closed the previous trading session at 31.55 up +0.25 0.80% with shares trading hands.